Key facts
- This page summarizes Claire Poll's Form 4 filing for Verona Pharma plc (VRNA).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Feb 2024, 18:10.
Claire Poll - 01 Feb 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)
- Reporting relationship
- General Counsel
- Issuer ticker
- VRNA
- Reported as of
- 01 Feb 2024
- Net transaction value
- -$237,197
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 18:10:37 UTC
- Prior SEC filing
- 03 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Claire Poll
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Claire Poll filed Form 4 for Verona Pharma plc (VRNA) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 03 Nov 2023.
- Current net transaction value: -$237,197.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRNA
transaction
Ordinary Shares
Tax liability
- Transaction value
- $237,197
- Shares
- -103,408
- Change %
- -5.6%
- Price
- $2.29*
- Shares after
- 1,740,079
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
VRNA
transaction
Ordinary Shares
Gift
- Transaction value
- $0
- Shares
- -116,592
- Change %
- -6.7%
- Price
- $0.000000
- Shares after
- 1,623,487
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F4
VRNA
transaction
Ordinary Shares
Gift
- Transaction value
- $0
- Shares
- +116,592
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 1,176,920
- Date
- 01 Feb 2024
- Ownership
- By Trust
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Footnote F2
Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
Footnote F3
The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2024 divided by eight (8).
Footnote F4
Consists of (i) 1,081,672 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 135,209 ADSs); (ii) 541,808 Ordinary Shares underlying 67,726 ADSs and (iii) 7 Ordinary Shares.
Footnote F5
Held by a family trust of which (a) the Reporting Person and spouse are trustees and (b) the Reporting Person and members of her immediate family are the sole beneficiaries of the trust.